TCCC, Taylor Automotive Family come together to form Taylor Cancer Research Center


TOLEDO, Ohio (WTVG) – The Toledo Clinic Cancer Centers and the Taylor Automotive Family have announced the formation of the Taylor Cancer Research Center, a not-for-profit clinical research program that will benefit all cancer patients in northwest Ohio.

According to TCCC, the Taylor family has donated $1 million to help facilitate innovative cancer treatments that are not currently available to cancer patients in the region.

“The Taylor Automotive family has a deep legacy of philanthropy in Toledo. Julie and I always believed that we were greatly blessed, and we have always felt the need to share these blessings with our community,” said Steve Taylor of the Taylor Automotive Family. “When we were introduced to Dr. John Nemunaitis and were able to review the tremendous accomplishments he has made in cancer research at other major cancer centers, we felt fortunate to have his expertise available in our community. We are excited to bring the same type of Precision-driven therapies that are currently available in other large cities across the United States to Toledo and the Northwest Ohio region.”

TCCC says Dr. John Nemunaitis is a nationally known expert in precision oncology. He has published over 500 peer review papers and book chapters, which have been cited over 30,000 times and has directed extensive interaction with FDA and clinical trial development of Precision therapy with multiple programs in the USA.

According to TCCC, Precision therapy specifically targets the mutated DNA which causes cancer growth. The Taylor Cancer Research Center will expand the testing opportunity of mutated cancer signals, followed by Precision therapy which impacts cancer targets to stop cancer growth. More than 100 Precision cancer therapies have been approved by the FDA over the last 10 years and even more therapies are currently being used for experimental Precision therapy through clinical trials.

“Our mission is to expand our current clinical trial research program and to now provide more cutting edge treatment close to home so that Toledo region patients can receive nationally acclaimed therapy without having to leave the area,” said Dr. Rex Mowat, a managing partner for TCCC. “We will welcome patients from other nearby cancer centers to benefit from ongoing trials we have available, and we will be reaching out to our colleagues at other cancer centers in the region, also encouraging their participation.”

See a spelling or grammar error in our story? Please include the title when you click here to report it.


Leave a Reply

Your email address will not be published. Required fields are marked *